Osimertinib Combo Lessens CNS Progression in EGFR NSCLC

Central nervous system (CNS) progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.

Related Keywords

Paris ,France General ,France ,Davida Litman ,Institut Gustave Roussy ,David Planchard ,European Society Of Medical Oncology Congress ,Astrazeneca ,Medical Oncology Congress ,Common Terminology Criteria ,Adverse Events ,Full Analysis ,Non Measurable Lesions ,Osimertinib ,